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MuscleA19-year-oldmuscularmalewith a history of epilepsy presented following two convulsive events. Levetiracetam
(LEV)was given as an additional therapy, resulting in amarked boost in creatine phosphokinase (CPK) that could
not easily be explained by renal dysfunction or rhabdomyolysis alone. Levetiracetam discontinuation caused CPK
levels to quickly normalize and should be considered in patients with persisting CPK elevations postconvulsive
seizure.
© 2014TheAuthors. PublishedbyElsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Levetiracetam (LEV) is used to treat generalized and partial seizures
of various etiologies. Three case reports document LEV-associated renal
compromise [1–3]. Rhabdomyolysis postconvulsive seizure may limit
kidney excretion of muscle breakdown products like creatine phospho-
kinase (CPK). In this case report, CPK elevations postseizure were
beyond what might otherwise be expected for mild rhabdomyolysis.
Possible mechanisms of protracted CPK elevation with LEV therapies
are brieﬂy discussed.
2. Case study
A 19-year-old right-handed male presented following a complex
partial seizure with secondary generalization in the setting of stress
and sleep deprivation. A second convulsive event lasting 2min occurred
in the emergency room. The patient was given 2 mg IV lorazepam,
2000 mg IV LEV, and 1200 mg oxcarbazepine (OXC), and no further
seizures occurred. The patient was maintained on LEV extended release
500 mg daily. The patient had not used LEV therapies prior to this
hospital admission.
Epilepsy etiologywas due to a right frontal arteriovenousmalforma-
tion (AVM) located in the left leg primary motor cortex (Fig. 1). The
AVM had previously been treated with gamma knife radiosurgery1 206 320 3088.
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ticonvulsant medications for this patient prior to the present hospitali-
zation included OXC 600 mg in the morning and 900 mg in the
afternoon or evening and lorazepam 0.5 mg prn for breakthrough sei-
zures. Of note, this patient is an avid weight lifter and very muscular
(Fig. 2). Although an avid weight lifter, the patient denied using supple-
mental agents for muscle bulking such as anabolic steroids or protein
powders.
Seizures postradiation manifested most commonly as nocturnal
convulsions. They occurred rarely in the daytime, and if they did, a
warning of lightheadedness, dizziness, and a lost sense of balance
would progress to bilateral muscle cramping, tonic–clonic movements,
tongue biting, and postictal confusion.
This admission was complicated by a rapid rise in CPK and mild
renal compromise, a new ﬁnding for the patient (Fig. 3). A renal ultra-
sound showed an increase in parenchymal echotexture, though no
hydronephrosis. A nephrology consultant did not suspect acute tubular
necrosis or other abnormalities. Maximum creatinine was 2.17 mg/dL
and had normalized prior to CPK maximum. The patient's CPK levels
were slow to resolve despite appropriate IVhydration. During the entire
period of CPK elevation, the patient's urine remained clear/yellow; trace
hematuria was noted only on day two. His day nine serum myoglobin
was 228 ng/mL (normal range: 10–92 ng/mL). An initial serum myo-
globin level was not checked.
With a marked drop of CPK on day 5 (CPK: 2736), the patient was
discharged on LEV and OXC combination therapy (Fig. 3). However,
blood work postdischarge showed CPK levels again in the 29,000
range, suggesting that the day ﬁve CPK measurement was a lab error.r the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Posterior to anterior cerebral angiogram of right ACA territory AVM (a) and lateral view of AVM (b).
Fig. 2. Patient's muscular right arm.
Fig. 3.Creatine phosphokinase (CPK) and creatinine trends byday postconvulsive seizures. In ad
is a lab error is indicated by an asterisk (*).
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showed a halving of CPK levels from 29,136 to 14,918 and a normal
level of creatinine. Creatine phosphokinase levels continued to decline
rapidly after LEV discontinuation, with normalization occurring nearly
a month later after resumption of a normal exercise regimen.
3. Discussion
Two convulsive seizures and subsequent LEV therapy led to a dra-
matic increase in CPK in this muscular male. Although this could indi-
cate a delayed rhabdomyolysis, the classic ﬁndings including marked
elevations in myoglobin/myoglobinuria, decreased urine output, and
muscle pain were not evident. Additionally, following muscular injury,
rhabdomyolysis-related CPK elevations typically occur maximally by
day three and decline by day ﬁve. The CPK elevation in this patient
was both delayed and persisted beyond the typical time frame of a
case of seizure-induced rhabdomyolysis [4], suggesting ongoing issues
of muscle breakdown despite cessation of seizure activities.
Creatine phosphokinase release occurs with insults to the sarcolem-
ma, most notably failure of ATP production or use. Levetiracetam is not
known to alter ATP functions. However, LEV was the only new drugdition, levetiracetam (LEV) begin and end dates are shown (gray arrows).Whatwebelieve
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tion closely mirror the trends in CPK levels in this patient. Although we
suspect that LEV may have contributed to CPK elevations in this heavily
muscled patient, those suspicions remain unproven.We are unaware of
any muscle enzyme or other neuromuscular problems in this patient. A
retrial of LEVwith CPK and renal function checks, amuscle biopsy, and a
repeat renal ultrasound are not planned, given that the patient's clinical
issues have resolved.
4. Conclusions
This case revealed a marked and dangerous increase in CPK levels
corresponding with modest LEV use. Although this scenario could
indicate a delayed rhabdomyolysis, the rapid decline in CPK with LEV
discontinuation suggests that, in this patient, LEV may have had effects
on kidney ﬁltration and/or muscle breakdown. Discontinuation of LEVin patientswith persisting CPK elevations postconvulsive seizure should
be considered.
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